Oral Solid Dosage Manufacturing Market Industry Trends and Global Forecasts to 2035, by Type of Finished Dosage Form, Type of Packaging, Scale of Operation, Company Size, Therapeutic Area, and Key Geographical Regions

1.1. Introduction
1.2. Key Market Insights
1.3. Scope of the Report
1.4. Research Methodology
1.5. Frequently Asked Questions
1.6. Chapter Outlines

3.1. Chapter Overview
3.2. Type of Dosage Forms
3.3. Overview of Oral Solid Dosage Forms
3.3.1. Components of Oral Solid Dosage Forms
3.3.2. Classification of Oral Solid Dosage Forms
3.3.3. Manufacturing of Oral Solid Dosage Forms
3.3.4. Emerging Trends in Oral Solid Dosage Manufacturing
3.4. Overview of Oral Solid Contract Manufacturing
3.4.1. Services Offered by CMOs and CDMOs for Oral Solid Manufacturing
3.4.2. Key Considerations While Selecting a CDMO or CMO Partner
3.4.3. Risks and Challenges Associated with Outsourcing Pharmaceutical Manufacturing Operations
3.5. Future Perspectives

4.1. Chapter Overview
4.2. Oral Solid Dosage CMOs: List of Companies
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size
4.2.3. Analysis by Location of Headquarters
4.2.4. Analysis by Company Ownership
4.2.5. Analysis by Type of Service(s) Offered
4.2.6. Analysis by Type of Finished Dosage Form
4.2.7. Analysis by Type of Tablet(S) Manufactured
4.2.8. Analysis by Type of Capsule(s) Manufactured
4.2.9. Analysis by Type of Multi-particulate(s) Manufactured
4.2.10. Analysis by Type of Primary Packaging Offered
4.2.11. Analysis by Scale of Operation
4.2.12. Analysis by High Potency Drug Manufacturing
4.2.13. Analysis by Availability of Continuous Manufacturing
4.2.14. Analysis by Regulatory Certifications / Accreditations

5.1. Chapter Overview
5.2. Assumptions and Key Parameters
5.3. Methodology
5.4. Company Competitiveness Analysis: Oral Solid Dosage Contract Manufacturers in North America
5.4.1. Peer Group I: Companies in the US
5.4.2. Peer Group II: Companies in Canada
5.5. Company Competitiveness Analysis: Oral Solid Dosage Contract Manufacturers based in Europe
5.5.1. Peer Group III: Companies in EU5
5.5.2. Peer Group IV: Other European Countries
5.6. Company Competitiveness Analysis: Oral Solid Contract Manufacturers based in Asia-Pacific and Rest of the World
5.6.1. Peer Group V: Companies in India
5.6.2. Peer Group VI: Companies in China
5.6.3. Peer Group VII: Companies in Japan
5.6.4. Peer Group VIII: Companies in Other Asia-Pacific and rest of the World
5.7. Company Competitiveness Analysis of Oral Solid Dosage Contract Manufacturers: Competitiveness Score of Top Service Providers

6.1. Chapter Overview
6.2. Key Assumptions and Methodology
6.3. Overall Landscape of Oral Solid Dosage Contract Manufacturing Facilities
6.4. Oral Solid Dosage Contract Manufacturers in North America
6.5. Oral Solid Dosage Contract Manufacturers in Europe
6.6. Oral Solid Dosage Contract Manufacturers in Asia-Pacific and Rest of the World

7.1. Chapter Overview
7.2. Oral Solid Dosage Contract Manufacturing Service Providers: North America
7.2.1. Alcami
7.2.1.1. Company Overview
7.2.1.2. Service Portfolio
7.2.1.2.1. Manufacturing Capabilities and Facilities
7.2.1.3. Recent Developments and Future Outlook
7.2.2. Cambrex
7.2.2.1. Company Overview
7.2.2.2. Service Portfolio
7.2.2.2.1. Manufacturing Capabilities and Facilities
7.2.2.3. Recent Developments and Future Outlook
7.2.3. Catalent
7.2.3.1. Company Overview
7.2.3.2. Financial Information
7.2.3.3. Service Portfolio
7.2.3.3.1. Manufacturing Capabilities and Facilities
7.2.3.4. Recent Developments and Future Outlook
7.3. Oral Solid Dosage Contract Manufacturing Service Providers: Europe
7.3.1. Aenova
7.3.1.1. Company Overview
7.3.1.2. Financial Information
7.3.1.3. Service Portfolio
7.3.1.3.1. Manufacturing Capabilities and Facilities
7.3.1.4. Recent Developments and Future Outlook
7.3.2. Almac
7.3.2.1. Company Overview
7.3.2.2. Financial Information
7.3.2.3. Service Portfolio
7.3.2.3.1. Manufacturing Capabilities and Facilities
7.3.2.4. Recent Developments and Future Outlook
7.3.3. Lonza
7.3.3.1. Company Overview
7.3.3.2. Financial Information
7.3.3.3. Service Portfolio
7.3.3.3.1. Manufacturing Capabilities and Facilities
7.3.3.4. Recent Developments and Future Outlook
7.4. Oral Solid Dosage Contract Manufacturing Service Providers: Asia-Pacific and Rest of the World
7.4.1. Hetero Drugs
7.4.1.1. Company Overview
7.4.1.2. Service Portfolio
7.4.1.2.1. Manufacturing Capabilities and Facilities
7.4.1.3. Recent Developments and Future Outlook
7.4.2. Ind-Swift Laboratories
7.4.2.1. Company Overview
7.4.2.2. Financial Information
7.4.2.3. Service Portfolio
7.4.2.3.1. Manufacturing Capabilities and Facilities
7.4.2.4. Recent Developments and Future Outlook
7.4.3. Rubicon Research
7.4.3.1. Company Overview
7.4.3.2. Service Portfolio
7.4.3.2.1. Manufacturing Capabilities and Facilities
7.4.3.3. Recent Developments and Future Outlook

8.1. Chapter Overview
8.2. Assumptions and Key Parameters
8.3. Oral Solid Dosage Manufacturers: Make versus Buy Decision Making
8.3.1. Scenario 1
8.3.2. Scenario 2
8.3.3. Scenario 3
8.3.4. Scenario 4
8.4. Concluding Remarks

9.1. Chapter Overview
9.2. Oral Solid Dosage Contract Manufacturers: Recent Expansions
9.2.1. Analysis by Year of Expansion
9.2.2. Analysis by Type of Expansion
9.2.3. Analysis by Year and Type of Expansion
9.2.4. Analysis by Type of Oral Solid Dosage Form(s) Involved
9.2.5. Analysis by Type of Expansion and Oral Solid Dosage Form(s) Involved
9.2.6. Analysis by Type of Service(s) Offered
9.2.7. Analysis by Scales of Operation
9.2.8. Analysis by Location of Facility
9.2.9. Expansions Focused on Highly Potent Compounds

10.1. Chapter Overview
10.2. Key Assumptions and Methodology
10.2.1. Oral Solid Dosage Contract Manufacturing: Annual Global Capacity (Number of Finished Dosages)
10.2.1.1. Analysis by Company Size
10.2.1.2. Analysis by Scale of Operation
10.2.1.3. Analysis by Type of Finished Dosage Form
10.2.1.4. Analysis by Location of Manufacturing Facility
10.2.1.5. Analysis by Company Size and Type of Finished Dosage Form
10.2.1.6. Analysis by Company Size and Location of Manufacturing Facility
10.2.1.7. Analysis by Scale of Operation and Location of Manufacturing Facility
10.2.2. Oral Solid Dosage Contract Manufacturing: Annual Global Capacity (Amount of API)
10.2.2.1. Analysis by Company Size
10.2.2.2. Analysis by Scale of Operation
10.2.2.3. Analysis by Type of Finished Dosage Form
10.2.2.4. Analysis by Company Size and Type of Finished Dosage Form
10.2.2.5. Analysis by Company Size and Location of Manufacturing Facility
10.2.2.6. Analysis by Scale of Operation and Location of Manufacturing Facility

11.1. Chapter Overview
11.2. Key Assumptions and Methodology
11.3. Overall Annual Demand for Oral Solid Doses, 2023-2035
11.4. Annual Outsourced Commercial Demand for Oral Solid Doses, 2023-2035
11.4.1. Annual Outsourced Commercial Demand for Oral Solid Doses: Distribution by Geography, 2023 and 2035
11.4.1.1. Annual Outsourced Commercial Demand for Oral Solid Doses in North America, 2023-2035
11.4.1.2. Annual Outsourced Commercial Demand for Oral Solid Doses in Europe, 2023-2035
11.4.1.3. Annual Outsourced Commercial Demand for Oral Solid Doses in Asia-Pacific and Rest of the World, 2023-2035
11.4.2. Annual Outsourced Commercial Demand for Oral Solid Doses: Distribution by Therapeutic Area, 2023 and 2035
11.4.2.1. Annual Outsourced Commercial Demand for Oral Solid Doses for Oncological Disorders, 2023-2035
11.4.2.2. Annual Outsourced Commercial Demand for Oral Solid Doses for Infectious Diseases, 2023-2035
11.4.2.3. Annual Outsourced Commercial Demand for Oral Solid Doses for Cardiovascular Disorders, 2023-2035
11.4.2.4. Annual Outsourced Commercial Demand for Oral Solid Doses for Metabolic Disorders, 2023-2035
11.4.2.5. Annual Outsourced Commercial Demand for Oral Solid Doses for Neurological Disorders, 2023-2035
11.4.2.6. Annual Outsourced Commercial Demand for Oral Solid Doses for Genetic Disorders, 2023-2035
11.4.2.7. Annual Outsourced Commercial Demand for Oral Solid Doses for Respiratory Disorders, 2023-2035
11.4.2.8. Annual Outsourced Commercial Demand for Oral Solid Doses for Immunological Disorders, 2023-2035
11.4.2.9. Annual Outsourced Commercial Demand for Oral Solid Doses for Other Disorders, 2023-2035
11.5. Annual Outsourced Clinical Demand for Oral Solid Doses, 2023-2035
11.5.1. Annual Outsourced Clinical Demand for Oral Solid Doses: Distribution by Trial Phase, 2023-2035
11.5.1.1. Annual Outsourced Clinical Demand for Oral Solid Doses in Phase I Trials, 2023-2035
11.5.1.2. Annual Outsourced Clinical Demand for Oral Solid Doses in Phase II Trials, 2023-2035
11.5.1.3. Annual Outsourced Clinical Demand for Oral Solid Doses in Phase III Trials, 2023-2035
11.6. Correlation between Annual Demand and Capacity

12.1. Chapter Overview
12.2. Key Parameters
12.3. Assumptions and Methodology
12.4. Sample Dataset for the Estimation of Total Cost of Ownership
12.5. Total Cost of Ownership for Oral Solid Dosage Contract Manufacturing Organizations, Y0-Y20
12.6. Total Cost of Ownership for Oral Solid Dosage Contract Manufacturing Organizations: Analysis by CapEx and OpEx, Y0 and Y20
12.6.1. Total Cost of Ownership for Oral Solid Contract Manufacturing Organizations: Analysis by CapEx, Y0
12.6.2. Total Cost of Ownership for Oral Solid Dosage Contract Manufacturing Organizations: Analysis by OpEx, Y0-Y20
12.7. Concluding Remarks

13.1. Chapter Overview
13.2. Regulatory Guidelines in North America
13.2.1. The US Scenario
13.2.1. Canadian Scenario
13.3. Regulatory Guidelines in Europe
13.4. Regulatory Guidelines in Asia-Pacific and Rest of the World
13.4.1. Chinese Scenario
13.4.2. Indian Scenario
13.4.3. Japanese Scenario
13.4.4. South Korean Scenario
13.4.5. Australian Scenario
13.4.6. Brazilian Scenario
13.5. Oral Solid Dosage CMOs: Information on Approval From Various Regulatory Authorities
13.6. Bubble Analysis: Regional Regulatory Summary

14.1. Chapter Overview
14.2. Taste Masking and Taste Assessment Service Providers
14.2.1. Analysis by Year of Establishment
14.2.2. Analysis by Company Size
14.2.3. Analysis by Location of Headquarters
14.2.4. Analysis by Year of Establishment and Location of Headquarters
14.3. Taste Masking and Taste Assessment Services: Overall Market Landscape
14.3.1. Analysis by Service(s) Offered
14.3.2. Analysis by Scale of Operation
14.3.3. Analysis by Other Service(s) Offered
14.3.4. Analysis by Type of Formulation(s)
14.3.5. Analysis by End Users
14.3.6. Analysis by Techniques Used for Taste Masking
14.3.7. Analysis by Branch of Healthcare
14.3.8. Analysis by Regional Capability

15.1. Chapter Overview
15.2. Bioavailability Enhancement Service Providers: Overall Market Landscape
15.2.1. Analysis by Year of Establishment
15.2.2. Analysis by Company Size
15.2.3. Analysis by Location of Headquarters
15.2.4. Analysis by Bioavailability Enhancement Principle
15.2.5. Analysis by Bioavailability Enhancement Approach
15.2.5.1. Analysis by Solid Dispersion Approaches
15.2.5.2. Analysis by Size Reduction Approaches
15.2.5.3. Analysis by Lipid-Based Approaches
15.2.5.4. Analysis by Other Bioavailability Enhancement Approaches
15.2.6. Analysis by Dosage Form
15.2.7. Analysis by Route of Administration

16.1. Chapter Overview
16.2. Forecast Methodology and Key Assumptions
16.2.1. Overall Oral Solid Dosage Contract Manufacturing Market, 2023-2035
16.2.2. Oral Solid Dosage Contract Manufacturing Market, 2023-2035: Distribution by Type of Finished Dosage Form
16.2.2.1. Tablet Manufacturing Market, 2023-2035
16.2.2.2. Capsule Manufacturing Market, 2023-2035
16.2.2.3. Powder Manufacturing Market, 2023-2035
16.2.2.4. Multi-particulates Manufacturing Market, 2023-2035
16.2.2.5. Other Finished Dosage Forms Manufacturing Market, 2023-2035
16.2.3. Oral Solid Dosage Contract Manufacturing Market, 2023-2035: Distribution by Type of Packaging
16.2.3.1. Oral Solid Dosage Contract Manufacturing Market for Bottles, 2023-2035
16.2.3.2. Oral Solid Dosage Contract Manufacturing Market for Blisters, 2023-2035
16.2.3.3. Oral Solid Dosage Contract Manufacturing Market for Inhalers, 2023-2035
16.2.3.4. Oral Solid Dosage Contract Manufacturing Market for Sachets, 2023-2035
16.2.3.5. Oral Solid Dosage Contract Manufacturing Market for Strips, 2023-2035
16.2.3.6. Oral Solid Dosage Contract Manufacturing Market for Stick Packs, 2023-2035
16.2.4. Oral Solid Dosage Contract Manufacturing Market, 2023-2035: Distribution by Scale of Operation
16.2.4.1. Oral Solid Dosage Contract Manufacturing Market for Pre-Commercial Scale, 2023-2035
16.2.4.2. Oral Solid Dosage Contract Manufacturing Market for Commercial Scale, 2023-2035
16.2.5. Oral Solid Dosage Contract Manufacturing Market, 2023-2035: Distribution by Company Size
16.2.5.1. Oral Solid Dosage Contract Manufacturing Market for Small Companies, 2023-2035
16.2.5.2. Oral Solid Dosage Contract Manufacturing Market for Mid-sized Companies, 2023-2035
16.2.5.3. Oral Solid Dosage Contract Manufacturing Market for Large Companies, 2023-2035
16.2.5.4. Oral Solid Dosage Contract Manufacturing Market for Very Large Companies, 2023-2035
16.2.6. Oral Solid Dosage Contract Manufacturing Market, 2023-2035: Distribution by Therapeutic Area
16.2.6.1. Oral Solid Dosage Contract Manufacturing Market for Oncological Disorders, 2023-2035
16.2.6.2. Oral Solid Dosage Contract Manufacturing Market for Infectious Diseases, 2023-2035
16.2.6.3. Oral Solid Dosage Contract Manufacturing Market for Cardiovascular Disorders, 2023-2035
16.2.6.4. Oral Solid Dosage Contract Manufacturing Market for Metabolic Disorders, 2023-2035
16.2.6.5. Oral Solid Dosage Contract Manufacturing Market for Neurological Disorders, 2023-2035
16.2.6.6. Oral Solid Dosage Contract Manufacturing Market for Genetic Disorders, 2023-2035
16.2.6.7. Oral Solid Dosage Contract Manufacturing Market for Respiratory Disorders, 2023-2035
16.2.6.8. Oral Solid Dosage Contract Manufacturing Market for Immunological Disorders, 2023-2035
16.2.6.9. Oral Solid Dosage Contract Manufacturing Market for Other Disorders, 2023-2035
16.2.7. Oral Solid Dosage Contract Manufacturing Market, 2023-2035: Distribution by Geographical Regions
16.2.7.1. Oral Solid Dosage Contract Manufacturing Market in North America, 2023-2035
16.2.7.2. Oral Solid Dosage Contract Manufacturing Market in Europe, 2023-2035
16.2.7.3. Oral Solid Dosage Contract Manufacturing Market in Asia-Pacific, 2023-2035
16.2.7.4. Oral Solid Dosage Contract Manufacturing Market in Latin America, 2023-2035
16.2.7.5. Oral Solid Dosage Contract Manufacturing Market in Middle East and North Africa, 2023-2035

Figure 2.1 Executive Summary: Market Landscape
Figure 2.2 Executive Summary: Service(s) Landscape
Figure 2.3 Executive Summary: Recent Expansions
Figure 2.4 Executive Summary: Capacity Analysis
Figure 2.5 Executive Summary: Demand Analysis
Figure 2.6 Executive Summary: Total Cost of Ownership
Figure 2.7 Executive Summary: Market Sizing and Opportunity Analysis
Figure 2.8 Executive Summary: Case Study on Taste Masking Service Providers
Figure 2.9 Executive Summary: Case Study on Bioavailability Enhancement Service Providers
Figure 3.1 Properties of Dosage Forms
Figure 3.2 Types of Dosage Forms
Figure 3.3 Advantages and Disadvantages of Oral Solid Dosage Forms
Figure 3.4 Properties of Pharmaceutical Excipient
Figure 3.5 Type of Oral Solid Dosage Forms
Figure 3.6 Classification of Orally Administered Tablets
Figure 3.7 Tablet Processing Methods
Figure 3.8 Oral Solid Dosage Manufacturing Process
Figure 3.9 Services Offered by CDMOs and CMOs for Oral Solid Dosage
Figure 3.10 Key Considerations While Selecting a CDMO or CMO Partner
Figure 4.1 Oral Solid Dosage Contract Manufacturers: Distribution by Year of Establishment
Figure 4.2 Oral Solid Dosage Contract Manufacturers: Distribution by Company Size
Figure 4.3 Oral Solid Dosage Contract Manufacturers: Distribution by Location of Headquarters
Figure 4.4 World Map Representation: Distribution by Geography
Figure 4.5 Oral Solid Dosage Contract Manufacturers: Distribution by Company Ownership
Figure 4.6 Oral Solid Dosage Contract Manufacturers: Distribution by Types of Service(s) Offered
Figure 4.7 Oral Solid Dosage Contract Manufacturers: Distribution by Type of Finished Dosage Form
Figure 4.8 Oral Solid Dosage Contract Manufacturers: Distribution by Type of Tablet(s) Manufactured
Figure 4.9 Oral Solid Dosage Contract Manufacturers: Distribution by Type of Capsule(s) Manufactured
Figure 4.10 Oral Solid Dosage Contract Manufacturers: Distribution by Type of Multi-particulate(s) Manufactured
Figure 4.11 Oral Solid Dosage Contract Manufacturers: Distribution by Type of Primary Packaging Offered
Figure 4.12 Oral Solid Dosage Contract Manufacturers: Distribution by Scale of Operation
Figure 4.13 Oral Solid Dosage Contract Manufacturers: Distribution by High Potency Drug Manufacturing
Figure 4.14 Oral Solid Dosage Contract Manufacturers: Distribution by Availability of Continuous Manufacturing
Figure 4.15 Oral Solid Dosage Contract Manufacturers: Distribution by Regulatory Certification / Accreditation
Figure 5.1 Company Competitiveness Analysis: Oral Solid Dosage Contract Manufacturers based in the US
Figure 5.2 Competitiveness Analysis: Oral Solid Dosage Contract Manufacturers based in Canada
Figure 5.3 Company Competitiveness Analysis: Oral Solid Dosage Contract Manufacturers Based in the EU5
Figure 5.4 Company Competitiveness Analysis: Oral Solid Dosage Contract Manufacturers Based in Other European Countries
Figure 5.5 Company Competitiveness Analysis: Oral Solid Dosage Contract Manufacturers Based in India
Figure 5.6 Company Competitiveness Analysis: Oral Solid Dosage Contract Manufacturers Based in China
Figure 5.7 Company Competitiveness Analysis: Oral Solid Dosage Contract Manufacturers Based in Japan
Figure 5.8 Company Competitiveness Analysis: Oral Solid Contract Manufacturers Based in Other Asia-Pacific and Rest of the World
Figure 5.9 Competitiveness Analysis of Oral Solid Dosage Contract Manufacturers: Competitiveness Score of Top Service Providers
Figure 6.1 Oral Solid Dosage Contract Manufacturers: Distribution by Location of Manufacturing Facilities
Figure 6.2 Oral Solid Dosage Contract Manufacturing: North America Scenario (I / II)
Figure 6.2 Oral Solid Dosage Contract Manufacturers: North America Scenario (II / II)
Figure 6.4 Oral Solid Dosage Contract Manufacturing: Europe Scenario (I / II)
Figure 6.5 Oral Solid Dosage Contract Manufacturers: Europe Scenario (II / II)
Figure 6.5 Oral Solid Dosage Contract Manufacturing: Asia-Pacific and Rest of the World Scenario (I / II)
Figure 6.6 Oral Solid Dosage Contract Manufacturers: Asia-Pacific and Rest of the World Scenario (II / II)
Figure 7.1 Catalent: Annual Revenues, FY 2017- FY 2022 (USD Billion)
Figure 7.2 Catalent: Distribution of FY 2022 Revenues by Business Segment
Figure 7.3 Aenova: Annual Revenues, FY 2017- FY 2021 (EUR Million)
Figure 7.4 Aenova: Distribution of FY 2021 Revenues by Type of Business Segment
Figure 7.5 Almac: Annual Revenues, FY 2017- FY 2021 (GBP Million)
Figure 7.6 Lonza: Annual Revenues, FY 2017- FY 2022 (CHF Billion)
Figure 7.7 Lonza: Distribution of FY 2022 Revenues by Type of Business Segment
Figure 7.8 Ind-Swift Laboratories: Annual Revenues, FY 2017- FY 2022 (INR Billion)
Figure 8.1 Make versus Buy Decision Making Framework
Figure 8.2 Make versus Buy Decision Making: Possible Scenario Descriptions
Figure 9.1 Recent Expansions: Cumulative Year-wise Trend, 2018-2022
Figure 9.2 Recent Expansions: Distribution by Type of Expansion
Figure 9.3 Recent Expansions: Distribution by Year and Type of Expansion
Figure 9.4 Recent Expansions: Distribution by Type of Oral Solid Dosage Form(s) Involved
Figure 9.5 Recent Expansions: Distribution by Type of Expansion and Oral Solid Dosage Form(s) Involved
Figure 9.6 Recent Expansions: Distribution by Type of Service(s) Offered
Figure 9.7 Recent Expansion: Distribution by Scale of Operation
Figure 9.8 Recent Expansions: Distribution by Location of Facility (Region-wise)
Figure 9.9 Recent Expansions: Distribution by Location of Facility (Country-wise)
Figure 9.10 Expansions Focused on Highly Potent Compounds: Distribution by Type of Expansion
Figure 10.1 Annual Minimum, Average and Maximum Oral Solid Dosage Contract Manufacturing Capacity (Distribution by Company Size: Sample Data Set
Figure 10.2 Distribution by Minimum, Average and Maximum Weight of Various Finished Dosage Forms: Sample Data Set
Figure 10.3 Distribution by Minimum, Average and Maximum Share of API in Various Finished Dosage Forms: Sample Data Set
Figure 10.4 Annual Global Oral Solid Dosage Contract Manufacturing Capacity (in terms of Number of Finished Dosage Units): Distribution by Company Size
Figure 10.5 Annual Global Oral Solid Dosage Contract Manufacturing Capacity (in terms of Number of Finished Dosage Forms): Distribution by Scale of Operation
Figure 10.6 Annual Global Oral Solid Dosage Contract Manufacturing Capacity (in terms of Number of Finished Dosage Forms): Distribution by Type of Finished Dosage Form
Figure 10.7 Annual Global Oral Solid Dosage Contract Manufacturing Capacity (in terms of Location of Manufacturing Facility): Distribution by Location of Manufacturing Facility
Figure 10.8 Annual Global Oral Solid Dosage Contract Manufacturing Capacity (in terms of Number of Finished Dosages): Distribution by Company Size and Type of Finished Dosage Form
Figure 10.9 Annual Global Oral Solid Dosage Contract Manufacturing Capacity (in terms of Number of Finished Dosages): Distribution by Company Size and Location of Manufacturing Facility
Figure 10.10 Annual Global Oral Solid Dosage Contract Manufacturing Capacity (in terms of Number of Finished Dosages): Distribution by Scale of Operation and Location of Manufacturing Facility
Figure 10.11 Annual Global Oral Solid Dosage Contract Manufacturing Capacity (in terms of Amount of API): Distribution by Company Size
Figure 10.12 Annual Global Oral Solid Dosage Contract Manufacturing Capacity (in terms of Number of Amount of API): Distribution by Scale of Operation
Figure 10.13 Annual Global Oral Solid Dosage Contract Manufacturing Capacity (in terms of Amount of API): Distribution by Type of Finished Dosage Form
Figure 10.14 Annual Global Oral Solid Dosage Contract Manufacturing Capacity (in terms of Amount of API): Distribution by Company Size and Type of Finished Dosage Form
Figure 10.15 Annual Global Oral Solid Dosage Contract Manufacturing Capacity (in terms of Amount of API): Distribution by Company Size and Location of Manufacturing Facility
Figure 10.16 Annual Global Oral Solid Dosage Contract Manufacturing Capacity (in terms of Amount of API): Distribution by Scale of Operation and Location of Manufacturing Facility
Figure 11.1 Demand Analysis: Annual Outsourced Demand for Oral Solid Doses, 2023-2035 (Metric Ton)
Figure 11.2 Annual Demand for Oral Solid Doses: Distribution by Scale of Operation, 2023 and 2035 (Metric Ton)
Figure 11.3 Annual Outsourced Commercial Demand for Oral Solid Doses, 2023-2035 (Metric Ton)
Figure 11.4 Commercial Outsourced Demand for Oral Solid Doses: Distribution by Geography, 2023 and 2035 (Metric Ton)
Figure 11.5 Commercial Outsourced Demand for Oral Solid Doses in North America, 2023-2035 (Metric Ton)
Figure 11.6 Commercial Outsourced Demand for Oral Solid Doses in Europe, 2023-2035 (Metric Ton)
Figure 11.7 Commercial Outsourced Demand for Oral Solid Doses in Asia-Pacific and Rest of the World, 2023-2035 (Metric Ton)
Figure 11.8 Commercial Outsourced Demand for Oral Solid Doses: Distribution by Therapeutic Area, 2023 and 2035 (Metric Ton)
Figure 11.9 Commercial Outsourced Demand for Oral Solid Doses for Oncological Disorders, 2023-2035 (Metric Ton)
Figure 11.10 Commercial Outsourced Demand for Oral Solid Doses for Infectious Diseases, 2023-2035 (Metric Ton)
Figure 11.11 Commercial Outsourced Demand for Oral Solid Doses for Cardiovascular Disorders, 2023-2035 (Metric Ton)
Figure 11.12 Commercial Outsourced Demand for Oral Solid Doses for Metabolic Disorders, 2023-2035 (Metric Ton)
Figure 11.13 Commercial Outsourced Demand for Oral Solid Doses for Neurological Disorders, 2023-2035 (Metric Ton)
Figure 11.14 Commercial Outsourced Demand for Oral Solid Doses for Genetic Disorders, 2023-2035 (Metric Ton)
Figure 11.15 Commercial Outsourced Demand for Oral Solid Doses for Respiratory Disorders, 2023-2035 (Metric Ton)
Figure 11.16 Commercial Outsourced Demand for Oral Solid Doses for Immunological Disorders, 2023-2035 (Metric Ton)
Figure 11.17 Commercial Outsourced Demand for Oral Solid Doses for Other Disorders, 2023-2035 (Metric Ton)
Figure 11.18 Annual Outsourced Clinical Demand for Oral Solid Doses, 2023-2035 (Metric Ton)
Figure 11.19 Clinical Outsourced Demand for Oral Solid Doses: Distribution by Trial Phase, 2023-2035 (Metric Ton)
Figure 11.20 Clinical Outsourced Demand for Oral Solid Doses in Phase I Trials, 2023-2035 (Metric Ton)
Figure 11.21 Clinical Outsourced Demand for Oral Solid Doses in Phase II Trials, 2023-2035 (Metric Ton)
Figure 11.22 Clinical Outsourced Demand for Oral Solid Doses in Phase III Trials, 2023-2035 (Metric Ton)
Figure 11.23 Annual Outsourced Demand and Capacity Utilization Rate: 2023-2035 (Metric Tons)
Figure 11.24 Oral Solid Dosage Contract Manufacturing: Correlation between Demand and Capacity, 2023-2035
Figure 12.1 Total Cost of Ownership: Types of Capital Expenditures (CapEx)
Figure 12.2 Total Cost of Ownership: Types of Operational Expenditures (OpEx)
Figure 12.3 Total Cost of Ownership for Oral Solid Dosage Contract Manufacturing Organizations, Y0-Y20 (USD Million)
Figure 12.4 Total Cost of Ownership for Oral Solid Dosage Contract Manufacturing Organizations: Distribution by CapEx and OpEx, Y0 and Y20 (USD Million)
Figure 12.5 Total Cost of Ownership for Oral Solid Dosage Contract Manufacturing Organizations: Distribution by CapEx and OpEx, Y0-Y20 (USD Million)
Figure 12.6 Total Cost of Ownership for Oral Solid Dosage Contract Manufacturing Organizations, Y0: Distribution of CapEx (USD Million)
Figure 12.7 Total Cost of Ownership for Oral Solid Dosage Contract Manufacturing Organizations, Y0: Distribution of OpEx (USD Million)
Figure 13.1 Key Regulatory Requirements for CMOs and CROs in India
Figure 13.2 Regulatory Landscape for Oral Solid Dosage CMOs: Distribution by Certifications / Accreditations Received
Figure 13.3 Bubble Analysis: Regional Regulatory Summary
Figure 14.1 Taste Masking and Taste Assessment Service Providers: Distribution by Year of Establishment
Figure 14.2 Taste Masking and Taste Assessment Service Providers: Distribution by Company Size
Figure 14.3 Taste Masking and Taste Assessment Service Providers: Distribution by Location of Headquarters
Figure 14.4 Taste Masking and Taste Assessment Service Providers: Distribution by Year of Establishment and Location of Headquarters
Figure 14.5 Taste Masking and Taste Assessment Services: Distribution by Service(s) Offered
Figure 14.6 Taste Masking and Taste Assessment Services: Distribution by Scale of Operation
Figure 14.7 Taste Masking and Taste Assessment Services: Distribution by Other Service(s) Offered
Figure 14.8 Taste Masking and Taste Assessment Services: Distribution by Type of Formulation(s)
Figure 14.9 Taste Masking and Taste Assessment Services: Distribution by End Users
Figure 14.10 Taste Masking and Taste Assessment Services: Distribution by Techniques Used for Taste Masking
Figure 14.11 Taste Masking and Taste Assessment Services: Distribution by Branch of Healthcare
Figure 14.12 Taste Masking and Taste Assessment Services: Distribution by Regional Capability
Figure 15.1 Bioavailability Enhancement Service Providers: Distribution by Year of Establishment
Figure 15.2 Bioavailability Enhancement Service Providers: Distribution by Company Size
Figure 15.3 Bioavailability Enhancement Service Providers: Distribution by Location of Headquarters (Region wise)
Figure 15.4 Bioavailability Enhancement Service Providers: Distribution by Location of Headquarters (Country-wise)
Figure 15.5 Bioavailability Enhancement Service Providers: Distribution by Bioavailability Enhancement Principle
Figure 15.6 Bioavailability Enhancement Service Providers: Distribution by Bioavailability Enhancement Approach
Figure 15.7 Bioavailability Enhancement Service Providers: Distribution by Solid Dispersion-based Approaches
Figure 15.8 Bioavailability Enhancement Service Providers: Distribution by Size Reduction Approaches
Figure 15.9 Bioavailability Enhancement Service Providers: Distribution by Lipid-based Approaches
Figure 15.10 Bioavailability Enhancement Service Providers: Distribution by Other Approaches
Figure 15.11 Bioavailability Enhancement Service Providers: Distribution by Dosage Form
Figure 15.12 Bioavailability Enhancement Service Providers: Distribution by Route of Administration
Figure 16.1 Oral Solid Dosage Contract Manufacturing: Market Forecast Approach
Figure 16.2 Global Oral Solid Dosage Contract Manufacturing Market, 2023-2035 (USD Billion)
Figure 16.3 Oral Solid Dosage Contract Manufacturing Market, 2023 and 2035: Distribution by Type of Finished Dosage Form
Figure 16.4 Tablet Manufacturing Market, 2023-2035 (USD Billion)
Figure 16.5 Capsule Manufacturing Market, 2023-2035 (USD Billion)
Figure 16.6 Powder Manufacturing Market, 2023-2035 (USD Billion)
Figure 16.7 Multi-particulates Manufacturing Market, 2023-2035 (USD Billion)
Figure 16.8 Other Finished Dosage Forms Manufacturing Market, 2023-2035 (USD Billion)
Figure 16.9 Oral Solid Dosage Contract Manufacturing Market, 2023 and 2035: Distribution by Type of Packaging (USD Billion)
Figure 16.10 Oral Solid Dosage Contract Manufacturing Market for Bottles, 2023-2035 (USD Billion)
Figure 16.11 Oral Solid Dosage Contract Manufacturing Market for Blisters, 2023-2035 (USD Billion)
Figure 16.12 Oral Solid Dosage Contract Manufacturing Market for Inhalers, 2023-2035 (USD Billion)
Figure 16.13 Oral Solid Dosage Contract Manufacturing Market for Sachets, 2023-2035 (USD Billion)
Figure 16.14 Oral Solid Dosage Contract Manufacturing Market for Strips, 2023-2035 (USD Billion)
Figure 16.15 Oral Solid Dosage Contract Manufacturing Market for Stick Packs, 2023-2035 (USD Billion)
Figure 16.16 Oral Solid Dosage Contract Manufacturing Market, 2023 and 2035: Distribution by Scale of Operation (USD Billion)
Figure 16.17 Oral Solid Dosage Contract Manufacturing Market for Pre-commercial Scale, 2023-2035 (USD Billion)
Figure 16.18 Oral Solid Dosage Contract Manufacturing Market for Commercial Scale, 2023-2035 (USD Billion)
Figure 16.19 Oral Solid Dosage Contract Manufacturing Market, 2023 and 2035: Distribution by Company Size (USD Billion)
Figure 16.20 Oral Solid Dosage Contract Manufacturing Market for Small Companies, 2023-2035 (USD Billion)
Figure 16.21 Oral Solid Dosage Contract Manufacturing Market for Mid-sized Companies, 2023-2035 (USD Billion)
Figure 16.22 Oral Solid Dosage Contract Manufacturing Market for Large Companies, 2023-2035 (USD Billion)
Figure 16.23 Oral Solid Dosage Contract Manufacturing Market for Very Large Companies, 2023-2035 (USD Billion)
Figure 16.24 Oral Solid Dosage Contract Manufacturing Market, 2023 and 2035: Distribution by Therapeutic Area (USD Billion)
Figure 16.25 Oral Solid Dosage Contract Manufacturing Market for Oncological Disorders, 2023-2035 (USD Billion)
Figure 16.26 Oral Solid Dosage Contract Manufacturing Market for Infectious Diseases, 2023-2035 (USD Billion)
Figure 16.27 Oral Solid Dosage Contract Manufacturing Market for Cardiovascular Disorders, 2023-2035 (USD Billion)
Figure 16.28 Oral Solid Dosage Contract Manufacturing Market for Metabolic Disorders, 2023-2035 (USD Billion)
Figure 16.29 Oral Solid Dosage Contract Manufacturing Market for Neurological Disorders, 2023-2035 (USD Billion)
Figure 16.30 Oral Solid Dosage Contract Manufacturing Market for Genetic Disorders, 2023-2035 (USD Billion)
Figure 16.31 Oral Solid Dosage Contract Manufacturing Market for Respiratory Disorders, 2023-2035 (USD Billion)
Figure 16.32 Oral Solid Dosage Contract Manufacturing Market for Immunological Disorders, 2023-2035 (USD Billion)
Figure 16.33 Oral Solid Dosage Contract Manufacturing Market for Other Disorders, 2023-2035 (USD Billion)
Figure 16.34 Oral Solid Dosage Contract Manufacturing Market, 2023 and 2035: Distribution by Key Geographical Regions (USD Billion)
Figure 16.35 Oral Solid Dosage Contract Manufacturing Market in North America, 2023-2035 (USD Billion)
Figure 16.36 Oral Solid Dosage Contract Manufacturing Market in Europe, 2023-2035 (USD Billion)
Figure 16.37 Oral Solid Dosage Contract Manufacturing Market in Asia-Pacific, 2023-2035 (USD Billion)
Figure 16.38 Oral Solid Dosage Contract Manufacturing Market in Latin America, 2023-2035 (USD Billion)
Figure 16.39 Oral Solid Dosage Contract Manufacturing Market in Middle East and North Africa, 2023-2035 (USD Billion)

Table 3.1 Commonly Used Excipients in Tablet Formulation
Table 3.2 Contrasting Characteristics: Film-coated and Sugar-coated Tablets
Table 3.3 Contrasting Characteristics: Hard Gelatin and Soft Gelatin Capsules
Table 4.1 Oral Solid Dosage Contract Manufacturing: List of Companies
Table 4.2 Oral Solid Dosage Contract Manufacturers: Information on Service(s) Offered
Table 4.3 Oral Solid Dosage Contract Manufacturers: Information on Type of Finished Dosage Form Manufactured
Table 4.4 Oral Solid Dosage Contract Manufacturers: Information on Type of Tablets and Capsules Manufactured
Table 4.5 Oral Solid Dosage Contract Manufacturers: Information on Type of Multi-particulate(s) Manufactured
Table 4.6 Oral Solid Dosage Contract Manufacturers: Information on Type of Primary Packaging Offered
Table 4.7 Oral Solid Dosage Contract Manufacturers: Information on Scale of Operation and Additional Manufacturing Capabilities
Table 4.8 Oral Solid Dosage Contract Manufacturers: Information on Regulatory Certifications and Accreditations
Table 6.1 Oral Solid Dosage Contract Manufacturers based in North America: Information on Headquarters, Year of Establishment, Company Size and Additional Manufacturing Capabilities
Table 6.2 Oral Solid Dosage Contract Manufacturers based in North America: Information on Scale of Operation, Type of Dosage Form and Number of Manufacturing Facilities
Table 6.3 Oral Solid Dosage Contract Manufacturers based in Europe: Information on Headquarters, Year of Establishment, Company Size and Additional Manufacturing Capabilities
Table 6.4 Oral Solid Dosage Contract Manufacturers based in Europe: Information Scale of Operation, Type of Dosage Form and Number of Manufacturing Facilities
Table 6.5 Oral Solid Dosage Contract Manufacturers based in Asia-Pacific and Rest of the World: Information on Headquarters, Year of Establishment, Company Size and Additional Manufacturing Capabilities
Table 6.6 Oral Solid Dosage Contract Manufacturers based in Asia-Pacific and Rest of the World: Information on Scale of Operation, Type of Dosage Form and Number of Manufacturing Facilities
Table 7.1 Oral Solid Dosage Contract Manufacturing Service Providers: List of Profiled Companies
Table 7.2 Alcami: Company Snapshot
Table 7.3 Alcami: Service Portfolio
Table 7.4 Alcami: Recent Developments and Future Outlook
Table 7.5 Cambrex: Company Snapshot
Table 7.6 Cambrex: Service Portfolio
Table 7.7 Cambrex: Oral Solid Manufacturing Facilities,
Table 7.8 Cambrex: Recent Developments and Future Outlook
Table 7.9 Catalent: Company Snapshot
Table 7.10 Catalent: Service Portfolio
Table 7.11 Catalent: Oral Solid Manufacturing Facilities
Table 7.12 Catalent: Recent Developments and Future Outlook
Table 7.13 Aenova: Company Snapshot
Table 7.14 Aenova: Service Portfolio
Table 7.15 Aenova: Oral Solid Manufacturing Facilities
Table 7.16 Aenova: Recent Developments and Future Outlook
Table 7.17 Almac: Company Snapshot
Table 7.18 Almac: Service Portfolio
Table 7.19 Almac: Oral Solid Manufacturing Facilities,
Table 7.20 Almac: Recent Developments and Future Outlook
Table 7.21 Lonza: Company Snapshot
Table 7.22 Lonza: Service Portfolio
Table 7.23 Lonza: Oral Solid Manufacturing Facilities
Table 7.24 Lonza: Recent Developments and Future Outlook
Table 7.25 Hetero Drugs: Company Snapshot
Table 7.26 Hetero Drugs: Service Portfolio
Table 7.27 Hetero Drugs: Recent Developments and Future Outlook
Table 7.28 Ind-Swift Laboratories: Company Snapshot
Table 7.29 Ind-Swift Laboratories: Service Portfolio
Table 7.30 Ind-Swift Laboratories: Oral Solid Manufacturing Facilities
Table 7.31 Rubicon Research: Company Snapshot
Table 7.32 Rubicon Research: Service Portfolio
Table 7.33 Rubicon Research: Oral Solid Manufacturing Facilities
Table 9.1 Oral Solid Dosage Contract Manufacturers: List of Recent Expansions, 2018-2022
Table 9.2 Recent Expansions: Information on Type of Oral Solid Dosage Form(s) Involved, Type of Service(s) Offered and Scale(s) of Operation, 2018-2022
Table 10.1 Average Annual Oral Solid Dosage Contract Manufacturing Capacity (Distribution by Type of Finished Dosage Form): Sample Data Set
Table 10.2 Average Annual Oral Solid Dosage Contract Manufacturing Capacity (Distribution by Company Size): Sample Data Set
Table 10.3 Distribution by Amount of API in Various Types of Oral Solid Dosage Forms: Sample Data Set
Table 10.4 Annual Global Oral Solid Dosage Contract Manufacturing Capacity (in terms of Number of Finished Dosages): Distribution by Company Size
Table 11.1 Annual Outsourced Demand for Oral Solid Doses, 2023-2035 (Metric Ton)
Table 11.2 Demand and Supply Analysis: Information on Annual Capacity Utilization Rates
Table 11.3 Annual Outsourced Demand (Base and Optimistic Scenarios): 2023-2035 (Metric Tons)
Table 12.1 Total Cost of Ownership: Sample Dataset for CapEx
Table 12.2 Total Cost of Ownership: Sample Dataset for OpEx
Table 13.1 FDA Quality Agreement versus EMA cGMP Regulations: A Comparative Analysis
Table 13.2 Health Canada’s Good Manufacturing Practices Guidelines for Tablets and Capsules
Table 13.3 Oral Solid Dosage CMOs: Information on Approval from Various Regulatory Authorities
Table 13.4 Key Regulatory Authorities: Comparison of NDA Approval Characteristics
Table 14.1 List of Taste Masking and Taste Assessment Service Providers
Table 14.2 Taste Masking and Taste Assessment Services: Information on Service(s) Offered, Scale of Operation and Other Service(s) Offered
Table 14.3 Taste Masking and Taste Assessment Services: Information on Type of Formulation
Table 14.4 Taste Masking and Taste Assessment Services: Information on End Users, Techniques Used for Taste Masking, Branch of Healthcare and Regional Capability
Table 15.1 List of Bioavailability Enhancement Service Providers
Table 15.2 Bioavailability Enhancement Service Providers: Information on Bioavailability Enhancement Principle
Table 15.3 Bioavailability Enhancement Service Providers: Information on Bioavailability Enhancement Approach
Table 15.4 Bioavailability Enhancement Service Providers: Information on Solid Dispersion Approaches
Table 15.5 Bioavailability Enhancement Service Providers: Information on Size Reduction Approaches
Table 15.6 Bioavailability Enhancement Service Providers: Information on Lipid-Based Approaches
Table 15.7 Bioavailability Enhancement Service Providers: Information on Other Approaches
Table 15.8 Bioavailability Enhancement Service Providers: Information on Dosage Form, ,
Table 15.9 Bioavailability Enhancement Service Providers: Information on Route of Administration
Table 17.1 Bushu Pharmaceuticals: Key Highlights
Table 19.1 Oral Solid Dosage Contract Manufacturers: Distribution by Year of Establishment
Table 19.2 Oral Solid Dosage Contract Manufacturers: Distribution by Company Size
Table 19.3 Oral Solid Dosage Contract Manufacturers: Distribution by Location of Headquarters
Table 19.4 Oral Solid Dosage Contract Manufacturers: Distribution by Location of Headquarters (Country-wise)
Table 19.5 Oral Solid Dosage Contract Manufacturers: Distribution by Company Ownership
Table 19.6 Oral Solid Dosage Contract Manufacturers: Distribution by Types of Services Offered
Table 19.7 Oral Solid Dosage Contract Manufacturers: Distribution by Type of Finished Dosage Form
Table 19.8 Oral Solid Dosage Contract Manufacturers: Distribution by Type of Tablet(s) Manufactured
Table 19.9 Oral Solid Dosage Contract Manufacturers: Distribution by Type of Capsule(s) Manufactured
Table 19.10 Oral Solid Dosage Contract Manufacturers: Distribution by Type of Multi-particulate(s)
Table 19.11 Oral Solid Dosage Contract Manufacturers: Distribution by Type of Primary Packaging Offered
Table 19.12 Oral Solid Dosage Contract Manufacturers: Distribution by Scale of Operation
Table 19.13 Oral Solid Dosage Contract Manufacturers: Distribution by High Potency Drug Manufacturing
Table 19.14 Oral Solid Dosage Contract Manufacturers: Distribution by Availability of Continuous Manufacturing
Table 19.15 Oral Solid Dosage Contract Manufacturers: Distribution by Regulatory Certifications and Accreditations
Table 19.16 Catalent: Annual Revenues, FY 2017 - FY 2022 (USD Billion)
Table 19.17 Aenova: Annual Revenues, FY 2017 - FY 2021 (EUR Million)
Table 19.18 Almac: Annual Revenues, FY 2017 - FY 2021 (GBP Million)
Table 19.19 Lonza: Annual Revenues, FY 2017 - FY 2022 (CHF Billion)
Table 19.20 Ind-Swift Laboratories: Annual Revenues, FY 2017 - FY 2022 (INR Billion)
Table 19.21 Recent Expansions: Cumulative Year-wise Trend, 2018-2022
Table 19.22 Recent Expansions: Distribution by Type of Expansion
Table 19.23 Recent Expansions: Distribution by Year and Type of Expansion
Table 19.24 Recent Expansions: Distribution by Type of Oral Solid Dosage Form(s) Involved
Table 19.25 Recent Expansions: Distribution by Type of Expansion and Oral Solid Dosage Form(s) Involved
Table 19.26 Recent Expansions: Distribution by Type of Service(s) Offered
Table 19.27 Recent Expansion: Distribution by Scale of Operation
Table 19.28 Recent Expansions: Distribution by Location of Facility (Region-wise)
Table 19.29 Recent Expansions: Distribution by Location of Facility (Country-wise)
Table 19.30 Expansions Focused on Highly Potent Compounds: Distribution by Type of Expansion
Table 19.31 Annual Global Capacity for Oral Solid Contract Manufacturing (Number of FDF Units): Distribution by Company Size and Range of Installed Capacity
Table 19.32 Average Annual Oral Solid Dosage Contract Manufacturing Capacity (Distribution by Average Weight of Various Finished Dosage Forms): Sample Data Set
Table 19.33 Average Annual Oral Solid Dosage Contract Manufacturing Capacity (Distribution by Share of API in Various Finished Dosage Forms): Sample Data Set
Table 19.34 Annual Global Oral Solid Dosage Contract Manufacturing Capacity (in terms of Number of Finished Dosage Units): Distribution by Company Size
Table 19.35 Annual Global Oral Solid Dosage Contract Manufacturing Capacity (in terms of Number of Finished Dosage Forms): Distribution by Scale of Operation
Table 19.36 Annual Global Oral Solid Dosage Contract Manufacturing Capacity (in terms of Number of Finished Dosage Forms): Distribution by Type of Finished Dosage Form
Table 19.37 Annual Global Oral Solid Dosage Contract Manufacturing Capacity (in terms of Location of Manufacturing Facility): Distribution by Location of Manufacturing Facility
Table 19.38 Annual Global Oral Solid Dosage Contract Manufacturing Capacity (in terms of Number of Finished Dosages): Distribution by Company Size and Type of Finished Dosage Form
Table 19.39 Annual Global Oral Solid Dosage Contract Manufacturing Capacity (in terms of Number of Finished Dosages): Distribution by Company Size and Location of Manufacturing Facility
Table 19.40 Installed Global Oral Solid Dosage Contract Manufacturing Capacity (in terms of Number of Finished Dosages): Distribution by Scale of Operation and Location of Manufacturing Facility
Table 19.41 Annual Global Oral Solid Dosage Contract Manufacturing Capacity (in terms of Amount of API Processed): Distribution by Company Size
Table 19.42 Annual Global Oral Solid Dosage Contract Manufacturing Capacity (in terms of Number of Finished Dosage Forms): Distribution by Scale of Operation
Table 19.43 Annual Global Oral Solid Dosage Contract Manufacturing Capacity (in terms of Amount of API): Distribution by Type of Finished Dosage Form
Table 19.44 Annual Global Oral Solid Dosage Contract Manufacturing Capacity (in terms of Amount of API): Distribution by Company Size and Type of Finished Dosage Form
Table 19.45 Annual Global Oral Solid Dosage Contract Manufacturing Capacity (in terms of Amount of API): Distribution by Company Size and Location of Manufacturing Facility
Table 19.46 Installed Global Oral Solid Dosage Contract Manufacturing Capacity (in terms of Amount of API): Distribution by Scale of Operation and Location of Manufacturing Facility
Table 19.47 Annual Demand and Capacity Utilization Rate: 2023-2035 (Metric Tons)
Table 19.48 Demand Analysis: Annual Demand for Oral Solid Doses, 2023-2035 (Metric Ton)
Table 19.49 Annual Demand for Oral Solid Doses: Distribution by Scale of Operation, 2023 and 2035 (Metric Ton)
Table 19.50 Annual Commercial Demand for Oral Solid Doses, 2023-2035 (Metric Ton)
Table 19.51 Commercial Demand for Oral Solid Doses: Distribution by Geography, 2023 and 2035 (Metric Ton)
Table 19.52 Commercial Demand for Oral Solid Doses in North America, 2023-2035 (Metric Ton)
Table 19.53 Commercial Demand for Oral Solid Doses in Europe, 2023-2035 (Metric Ton)
Table 19.54 Commercial Demand for Oral Solid Doses in Asia-Pacific and Rest of the World, 2023-2035 (Metric Ton)
Table 19.55 Commercial Demand for Oral Solid Doses: Distribution by Therapeutic Area, 2023 and 2035 (Metric Ton)
Table 19.56 Commercial Demand for Oral Solid Doses for Oncological Disorders, 2023-2035 (Metric Ton)
Table 19.57 Commercial Demand for Oral Solid Doses for Infectious Diseases, 2023-2035 (Metric Ton)
Table 19.58 Commercial Demand for Oral Solid Doses for Cardiovascular Disorders, 2023-2035 (Metric Ton)
Table 19.59 Commercial Demand for Oral Solid Doses for Metabolic Disorders, 2023-2035 (Metric Ton)
Table 19.60 Commercial Demand for Oral Solid Doses for Neurological Disorders, 2023-2035 (Metric Ton)
Table 19.61 Commercial Demand for Oral Solid Doses for Genetic Disorders, 2023-2035 (Metric Ton)
Table 19.62 Commercial Demand for Oral Solid Doses for Respiratory Disorders, 2023-2035 (Metric Ton)
Table 19.63 Commercial Demand for Oral Solid Doses for Immunological Disorders, 2023-2035 (Metric Ton)
Table 19.64 Commercial Demand for Oral Solid Doses for Other Disorders, 2023-2035 (Metric Ton)
Table 19.65 Annual Clinical Demand for Oral Solid Doses, 2023-2035 (Metric Ton)
Table 19.66 Clinical Demand for Oral Solid Doses: Distribution by Trial Phase, 2023-2035 (Metric Ton)
Table 19.67 Clinical Demand for Oral Solid Doses in Phase I Trials, 2023-2035 (Metric Ton)
Table 19.68 Clinical Demand for Oral Solid Doses in Phase II Trials, 2023-2035 (Metric Ton)
Table 19.69 Clinical Demand for Oral Solid Doses in Phase III Trials, 2023-2035 (Metric Ton)
Table 19.70 Total Cost of Ownership for Oral Solid Dosage Contract Manufacturing Organizations, Y0-Y20 (USD Million)
Table 19.71 Total Cost of Ownership for Oral Solid Dosage Contract Manufacturing Organizations: Distribution by CapEx and OpEx, Y0 and Y20 (USD Million)
Table 19.72 Total Cost of Ownership for Oral Solid Dosage Contract Manufacturing Organizations: Distribution by CapEx and OpEx, Y0-Y20 (USD Million)
Table 19.73 Total Cost of Ownership for Oral Solid Dosage Contract Manufacturing Organizations, Y0: Distribution of CapEx (USD Million)
Table 19.74 Total Cost of Ownership for Oral Solid Dosage Contract Manufacturing Organizations, Y0: Distribution of OpEx (USD Million)
Table 19.75 Taste Masking and Taste Assessment Service Providers: Distribution by Year of Establishment
Table 19.76 Taste Masking and Taste Assessment Service Providers: Distribution by Company Size
Table 19.77 Taste Masking and Taste Assessment Service Providers: Distribution by Location of Headquarters
Table 19.78 Taste Masking and Taste Assessment Service Providers: Distribution by Year of Establishment and Location of Headquarters
Table 19.79 Taste Masking and Taste Assessment Services: Distribution by Service(s) Offered
Table 19.80 Taste Masking and Taste Assessment Services: Distribution by Scale of Operation
Table 19.81 Taste Masking and Taste Assessment Services: Distribution by Other Service(s) Offered
Table 19.82 Taste Masking and Taste Assessment Services: Distribution by Type of Formulation(s)
Table 19.83 Taste Masking and Taste Assessment Services: Distribution by End Users
Table 19.84 Taste Masking and Taste Assessment Services: Distribution by Techniques Used for Taste Masking
Table 19.85 Taste Masking and Taste Assessment Services: Distribution by Branch of Healthcare
Table 19.86 Taste Masking and Taste Assessment Services: Distribution by Regional Capability
Table 19.87 Bioavailability Enhancement Service Providers: Distribution by Year of Establishment
Table 19.88 Bioavailability Enhancement Service Providers: Distribution by Company Size
Table 19.89 Bioavailability Enhancement Service Providers: Distribution by Location of Headquarters (Region-wise)
Table 19.90 Bioavailability Enhancement Service Providers: Distribution by Location of Headquarters (Country-wise)
Table 19.91 Bioavailability Enhancement Service Providers: Distribution by Bioavailability Enhancement Principle
Table 19.92 Bioavailability Enhancement Service Providers: Distribution by Bioavailability Enhancement Approach
Table 19.93 Bioavailability Enhancement Service Providers: Distribution by Solid Dispersion-based Approaches
Table 19.94 Bioavailability Enhancement Service Providers: Distribution by Size Reduction Approaches
Table 19.95 Bioavailability Enhancement Service Providers: Distribution by Lipid-based Approaches
Table 19.96 Bioavailability Enhancement Service Providers: Distribution by Other Approaches
Table 19.97 Bioavailability Enhancement Service Providers: Distribution by Dosage Form
Table 19.98 Bioavailability Enhancement Service Providers: Distribution by Route of Administration
Table 19.99 Global Oral Solid Dosage Contract Manufacturing Market, 2023-2035 (USD Billion)
Table 19.100 Oral Solid Dosage Contract Manufacturing Market, 2023 and 2035: Distribution by Type of Finished Dosage Form
Table 19.101 Tablet Manufacturing Market, 2023-2035 (USD Billion)
Table 19.102 Capsule Manufacturing Market, 2023-2035 (USD Billion)
Table 19.103 Powder Manufacturing Market, 2023-2035 (USD Billion)
Table 19.104 Multi-particulates Manufacturing Market, 2023-2035 (USD Billion)
Table 19.105 Other Finished Dosage Forms Manufacturing Market, 2023-2035 (USD Billion)
Table 19.106 Oral Solid Dosage Contract Manufacturing Market, 2023 and 2035: Distribution by Type of Packaging
Table 19.107 Oral Solid Dosage Contract Manufacturing Market for Bottles, 2023-2035 (USD Billion)
Table 19.108 Oral Solid Dosage Contract Manufacturing Market for Blisters, 2023-2035 (USD Billion)
Table 19.109 Oral Solid Dosage Contract Manufacturing Market for Inhalers, 2023-2035 (USD Billion)
Table 19.110 Oral Solid Dosage Contract Manufacturing Market for Sachets, 2023-2035 (USD Billion)
Table 19.111 Oral Solid Dosage Contract Manufacturing Market for Strips, 2023-2035 (USD Billion)
Table 19.112 Oral Solid Dosage Contract Manufacturing Market for Stick Packs, 2023-2035 (USD Billion)
Table 19.113 Oral Solid Dosage Contract Manufacturing Market, 2023 and 2035: Distribution by Scale of Operation
Table 19.114 Oral Solid Dosage Contract Manufacturing Market for Pre-commercial Scale, 2023-2035 (USD Billion)
Table 19.115 Oral Solid Dosage Contract Manufacturing Market for Commercial Scale, 2023-2035 (USD Billion)
Table 19.116 Oral Solid Dosage Contract Manufacturing Market, 2023 and 2035: Distribution by Company Size
Table 19.117 Oral Solid Dosage Contract Manufacturing Market for Small Companies, 2023-2035 (USD Billion)
Table 19.118 Oral Solid Dosage Contract Manufacturing Market for Mid-sized Companies, 2023-2035 (USD Billion)
Table 19.119 Oral Solid Dosage Contract Manufacturing Market for Large Companies, 2023-2035 (USD Billion)
Table 19.120 Oral Solid Dosage Contract Manufacturing Market for Very Large Companies, 2023-2035 (USD Billion)
Table 19.121 Oral Solid Dosage Contract Manufacturing Market, 2023 and 2035: Distribution by Therapeutic Area
Table 19.122 Oral Solid Dosage Contract Manufacturing Market for Oncological Disorders, 2023-2035 (USD Billion)
Table 19.123 Oral Solid Dosage Contract Manufacturing Market for Infectious Diseases, 2023-2035 (USD Billion)
Table 19.124 Oral Solid Dosage Contract Manufacturing Market for Cardiovascular Disorders, 2023-2035 (USD Billion)
Table 19.125 Oral Solid Dosage Contract Manufacturing Market for Metabolic Disorders, 2023-2035 (USD Billion)
Table 19.126 Oral Solid Dosage Contract Manufacturing Market for Neurological Disorders, 2023-2035 (USD Billion)
Table 19.127 Oral Solid Dosage Contract Manufacturing Market for Genetic Disorders, 2023-2035 (USD Billion)
Table 19.128 Oral Solid Dosage Contract Manufacturing Market for Respiratory Disorders, 2023-2035 (USD Billion)
Table 19.129 Oral Solid Dosage Contract Manufacturing Market for Immunological Disorders, 2023-2035 (USD Billion)
Table 19.130 Oral Solid Dosage Contract Manufacturing Market for Other Disorders, 2023-2035 (USD Billion)
Table 19.131 Oral Solid Dosage Contract Manufacturing Market, 2023 and 2035: Distribution by Geographical Regions (USD Billion)
Table 19.132 Oral Solid Dosage Contract Manufacturing Market in North America, 2023-2035 (USD Billion)
Table 19.133 Oral Solid Dosage Contract Manufacturing Market in Europe, 2023-2035 (USD Billion)
Table 19.134 Oral Solid Dosage Contract Manufacturing Market in Asia-Pacific, 2023-2035 (USD Billion)
Table 19.135 Oral Solid Dosage Contract Manufacturing Market in Latin America, 2023-2035 (USD Billion)
Table 19.136 Oral Solid Dosage Contract Manufacturing Market in Middle East and North Africa, 2023-2035 (USD Billion)